A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

Phase 1 Completed 28 enrolled Bristol-Myers Squibb

Non-randomizedCrossoverOpen-labelBasic science

Summary

The study is being conducted to assess the effects of co-administration of itraconazole or diltiazem, respectively, on the pharmacokinetic (PK) parameters Cmax, AUC(INF), and AUC(0-T) of BMS-986177

Timeline

Start: 2016-07
Primary completion: 2016-08
Completion: 2016-08

Publications

Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B. Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. Cardiol Ther. 2022 Sep;11(3):407-419. doi: 10.1007/s40119-022-00266-6. Epub 2022 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diltiazem	Small molecule	240 mg	Oral
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	Milvexian	Small molecule	30 mg	Oral

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications